Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Net Income (2016 - 2025)

Historic Net Income for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' Net Income rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 10650.12%. This contributed to the annual value of -$10.7 million for FY2024, which is 28473.42% down from last year.
  • Marker Therapeutics' Net Income amounted to -$2.0 million in Q3 2025, which was up 1341.01% from -$4.1 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Net Income peaked at $6.6 million during Q2 2023, and registered a low of -$9.8 million during Q1 2022.
  • Over the past 4 years, Marker Therapeutics' median Net Income value was -$2.3 million (recorded in 2024), while the average stood at -$2.2 million.
  • As far as peak fluctuations go, Marker Therapeutics' Net Income skyrocketed by 26489.77% in 2023, and later crashed by 591800.31% in 2024.
  • Over the past 4 years, Marker Therapeutics' Net Income (Quarter) stood at -$813062.0 in 2022, then skyrocketed by 92.26% to -$62939.0 in 2023, then tumbled by 5918.0% to -$3.8 million in 2024, then skyrocketed by 47.23% to -$2.0 million in 2025.
  • Its Net Income was -$2.0 million in Q3 2025, compared to -$4.1 million in Q2 2025 and -$4.4 million in Q1 2025.